Company / Shareholders' Equity
Johnson & Johnson Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$81.5B
FY2025
5-year range
$68.8B / $81.5B
FY2021-FY2025
Trend
+14.1%
vs FY2024
Sector context
#2 of 213
Health Care
What the data says
Among 213 Health Care companies, Johnson & Johnson is in the top 1% for shareholders' equity. Shareholders' Equity has fluctuated over the past 10 years, ranging from $59.5B in FY2019 to $81.5B in FY2025.
Based on SEC 10-K filings.
$81.5B in FY2025 with a 5-year CAGR of +5.2%. Ranks 2nd among 213 companies in Health Care.
Improved from $68.8B to $81.5B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +2.0%
- 5-Year CAGR
- +5.2%
- 10-Year CAGR
- -
Sector benchmark
+3099.2% above sector average
Key checks
Key Insights
- 5-year CAGR of +5.2%, indicating consistent growth.
- In FY2025, shareholders' equity increased 14.1% year-over-year.
- Ranks #2 out of 213 companies in the Health Care sector.
- Lowest shareholders' equity in the period was in FY2019.
Company context
Key Data Points
- Strong profit margin: 27.3%
- Strong return on equity: 31.7%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $81.5B | +14.1% |
| FY2024 | $71.5B | +3.9% |
| FY2023 | $68.8B | -10.5% |
| FY2022 | $76.8B | +3.8% |
| FY2021 | $74.0B | +17.0% |
| FY2020 | $63.3B | +6.4% |
| FY2019 | $59.5B | -0.5% |
| FY2018 | $59.8B | -0.7% |
| FY2017 | $60.2B | -14.6% |
| FY2016 | $70.4B | -1.0% |
As of FY2025 · SEC 10-K · Updated Mar 11, 2026